Telehealth Firms Indicted in $100 Million Online Adderall Conspiracy
San Francisco, Thursday, 18 December 2025.
Federal prosecutors have indicted Done Global and Mindful Mental Wellness in a massive $100 million conspiracy, alleging the firms operated a ‘pill mill’ disguised as digital healthcare. The indictment reveals that over 40 million Adderall pills were distributed to patients—often without legitimate medical need—driven by a subscription model that prioritized revenue over safety. This legal escalation signals a severe regulatory crackdown on telehealth platforms exploiting the online prescription market during a national shortage.
The Mechanics of a $100 Million Scheme
On December 17, 2025, federal prosecutors announced the indictment of California-based Done Global Inc. and Florida-based Mindful Mental Wellness P.A. (MMW) following a grand jury decision in San Francisco the previous day [1][3]. The charges depict a sophisticated operation where patient safety was allegedly sacrificed for profit, generating over $100 million in revenue since the onset of the COVID-19 pandemic [1]. According to the Department of Justice, the companies facilitated the distribution of over 40 million Adderall pills and other stimulants, treating these controlled substances as commodities to be marketed through subscription services rather than carefully overseen medications [1][3].
Evasion and Obstruction Tactics
As scrutiny mounted, the firms allegedly engaged in deceptive practices to maintain their revenue streams. By 2023, after several major pharmacies began blocking prescriptions from Done Health, the company incorporated Mindful Mental Wellness to circumvent these restrictions and mislead insurers [2][4]. The indictment further alleges that Done Global conspired to alter, destroy, and conceal records after receiving a grand jury subpoena, attempting to hide the extent of their operations from federal investigators [1][2]. U.S. Attorney Craig Missakian noted that instead of using technology to enhance care, the defendants viewed telehealth as a mechanism to “provide unfettered access” to stimulants [3].
Regulatory Context Amidst Shortages
The prosecution of Done Global and MMW occurs against the backdrop of a prolonged public health challenge. The United States is currently navigating the third year of a nationwide Adderall shortage [1]. In 2024, the FDA identified increased prescribing driven by telemedicine growth as a contributing factor to these supply constraints, alongside manufacturing issues [1]. The Drug Enforcement Administration has condemned the business model employed by Done Global, with Assistant Administrator Cheri Oz stating that the firm “prioritized profit over patient safety and public health” by distributing millions of pills for non-legitimate purposes [2].